We are a specialty biopharmaceutical company focused on commercializing KRYSTEXXA throughout the world. KRYSTEXXA was approved for marketing by the U.S. Food and Drug Administration, or FDA, on September 14, 2010 and became commercially available in the United States by prescription on December 1, 2010, when we commenced sales and shipments to our network of specialty and wholesale distributors. On January 7, 2013, our wholly owned subsidiary, Savient Pharma Ireland Limited was granted a marketing authorization from the European Commission for KRYSTEXXA to be marketed in the European Union, or EU. KRYSTEXXA was approved in the EU for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated. We continue to focus on our pre-launch activities for KRYSTEXXA in the EU, while we advance our examination of collaboration and partnership opportunities for the commercial launch of KRYSTEXXA in the EU. At this time, we cannot estimate the timeline for the consummation of any potential deal for EU commercialization, for which a transaction must be in place prior to a launch in that region. We see opportunity for KRYSTEXXA in other regions around the world and thus, we are also continuing to explore collaboration and partnership opportunities for the regulatory approval and commercialization of KRYSTEXXA outside of the United States and EU. On February 19, 2013, we announced that we entered into an agreement with Swedish Orphan Biovitrum AB, or Sobi, an international specialty healthcare company dedicated to rare diseases, for the co-promotion of Kineret® , a treatment for rheumatoid arthritis, in the U.S. Under the terms of the agreement, Sobi has granted to us the exclusive right to co-promote the sale of Kineret with Sobi in the U.S. We will market and promote Kineret beginning April 1, 2013. We earn a co-promotion fee from this arrangement based upon fifty percent of incremental gross profit earned from Kineret in a year as compared to 2012 adjusted gross profit as the base year.
Company profile
Ticker
SVNT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bio Technology General Corp
SEC CIK
Corporate docs
IRS number
133033811
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
20 Mar 19
CT ORDER
Confidential treatment order
23 May 17
8-K
Regulation FD Disclosure
30 May 14
8-K
Bankruptcy or Receivership
20 May 14
8-K
Regulation FD Disclosure
17 Apr 14
8-K
Regulation FD Disclosure
21 Mar 14
8-K
Regulation FD Disclosure
18 Mar 14
8-K
Regulation FD Disclosure
21 Feb 14
8-K
Regulation FD Disclosure
11 Feb 14
8-K
Regulation FD Disclosure
22 Jan 14
Institutional ownership, Q4 2020
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IFP Advisors | 0.00 | $0.00 |